Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Invested Capital: 2022-2025

Historic Invested Capital for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $219.0 million.

  • Taysha Gene Therapies' Invested Capital rose 146.62% to $219.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $219.0 million, marking a year-over-year increase of 146.62%. This contributed to the annual value of $111.5 million for FY2024, which is 48.83% up from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Invested Capital is $219.0 million, which was down 11.96% from $248.7 million recorded in Q2 2025.
  • Taysha Gene Therapies' 5-year Invested Capital high stood at $248.7 million for Q2 2025, and its period low was -$37.1 million during Q2 2023.
  • In the last 3 years, Taysha Gene Therapies' Invested Capital had a median value of $74.9 million in 2023 and averaged $81.8 million.
  • The largest annual percentage gain for Taysha Gene Therapies' Invested Capital in the last 5 years was 7,796.42% (2023), contrasted with its biggest fall of 214.17% (2023).
  • Quarterly analysis of 4 years shows Taysha Gene Therapies' Invested Capital stood at $949,000 in 2022, then skyrocketed by 7,796.42% to $74.9 million in 2023, then surged by 48.83% to $111.5 million in 2024, then skyrocketed by 146.62% to $219.0 million in 2025.
  • Its Invested Capital stands at $219.0 million for Q3 2025, versus $248.7 million for Q2 2025 and $55.1 million for Q1 2025.